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ABSTRACT: The identiﬁcation of eﬀective polypeptide
ligands for magnetic iron oxide nanoparticles (IONPs)
could considerably accelerate the high-throughput analysis
of IONP-based reagents for imaging and cell labeling. We
developed a procedure for screening IONP ligands and
applied it to compare candidate peptides that incorporated
carboxylic acid side chains, catechols, and sequences
derived from phage display selection. We found that
only L-3,4-dihydroxyphenylalanine (DOPA)-containing
peptides were suﬃcient to maintain particles in solution.
We used a DOPA-containing sequence motif as the
starting point for generation of a further library of over 30
peptides, each of which was complexed with IONPs and
evaluated for colloidal stability and magnetic resonance
imaging (MRI) contrast properties. Optimal properties
were conferred by sequences within a narrow range of
biophysical parameters, suggesting that these sequences
could serve as generalizable anchors for formation of
polypeptide−IONP complexes. Diﬀerences in the amino
acid sequence aﬀected T1- and T2-weighted MRI contrast
without substantially altering particle size, indicating that
the microstructure of peptide-based IONP coatings exerts
a substantial inﬂuence and could be manipulated to tune
properties of targeted or responsive contrast agents. A
representative peptide−IONP complex displayed stability
in biological buﬀer and induced persistent MRI contrast in
mice, indicating suitability of these species for in vivo
molecular imaging applications.
Magnetic iron oxide nanoparticles (IONPs) have becomepopular tools for biotechnology and medical imaging,1
and techniques for rapid molecular engineering of IONP
species could be enormously valuable for design and
optimization of magnetic reagents. In most applications,
IONP cores are coated with a passivating layer of hydrophilic
material, such as polyethylene glycol (PEG) or dextran, and
then conjugated to functional moieties that promote target
binding or detection of analytes.2 The complexity of multistep
synthesis and conjugation chemistry is an impediment to
production of large collections of IONPs. In addition,
traditional passivation and functionalization of IONPs adds
substantial bulk to IONPs, limiting steric access to the mineral
cores where magnetic ﬁelds are highest; this in turn limits the
eﬀectiveness and manipulability of IONPs for molecular-scale
applications.
In an eﬀort to discover simple and versatile IONP
modiﬁcation strategies suitable for high-throughput analysis
and identiﬁcation of desirable IONP reagents, we explored the
ability of short polypeptides to act as chemically tunable direct
iron oxide ligands. Peptides that bind iron oxide cores could
form an ideal basis for large-scale investigation of the
determinants of IONP properties in applications such as
magnetic resonance imaging (MRI) contrast manipulation.
Eﬀective stabilization of IONP cores by individual peptide
sequences has not previously been demonstrated, but both
functional groups and peptide sequences with iron oxide
binding characteristics have been identiﬁed. We constructed a
small initial set of 6−15 residue sequences using some of these
moieties, including carboxylate3 and catechol groups,4,5 as well
as peptide motifs derived from phage display screens for
binding to magnetite6 (DSPHRHS) and hematite7
(LSTVQTISPSNH). Catechol-containing sequences were
formulated with variations in net charge and with polyserine
moieties to ensure hydrophilicity.
In order to screen the peptide library for IONP binding and
MRI contrast properties, we developed a procedure for parallel
analysis of candidate peptide−IONP complexes. Iron oxide
cores were prepared for complexation by exchanging oleate-
stabilized iron oxide nanocrystals into aqueous solutions of
tetramethylammonium hydroxide (TMA) at basic pH (Figure
1a).8,9 Candidate peptides from the initial collection were
added to the resulting TMA-associated cores and neutralized by
dilution into phosphate-buﬀered saline (PBS). Peptides were
assessed for their ability to stabilize IONPs in the resulting
solutions by evaluating relative optical density at 450 nm
(OD450) following formulation (Figure 1b). Lower stability
results in precipitation and lower OD450 (Figure 1b images).
Examination of results from the initial library showed that only
an anionic L-3,4-dihydroxyphenylalanine (DOPA)-terminated
peptide, SSSSSSDDZ, where Z = DOPA, provided signiﬁcant
enhancement of stability with respect to the negative control of
no peptide addition (p = 0.02, n = 3). The stabilization aﬀorded
by SSSSSSDDZ was statistically indistinguishable from that
provided by citrate, an established IONP ligand (p = 0.4, n =
3).10 Among peptides that did not appear to stabilize IONPs in
PBS were the two phage display motifs, two polyglutamate-
containing peptides, and additional sequences that lacked either
acidic residues or a DOPA moiety. Some of these sequences,
including polyacidic but not phage display peptides, were better
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able to stabilize IONPs under low salt conditions (Supporting
Information), suggesting that poor performance of some of the
candidate peptides in the absorbance assay of Figure 1 may
result from a combination of low aﬃnity for IONP cores and
lack of electrostatic properties conducive to colloidal behavior.
The assay conditions applied in our screening procedure are
likely therefore to select simultaneously for eﬀective peptide−
IONP binding and complexes with favorable colloidal stability.
To further probe molecular determinants of IONP
stabilization by SSSSSSDDZ, a second set of peptides was
constructed. OD450 results obtained using this library (Figure
1b and Supporting Information) indicated that replacement of
the catechol by phenol (Z to Y substitution) or addition of
DOPA to a phage display-selected sequence failed to stabilize
colloidal IONPs. Separation of aspartate residues from DOPA,
substitution of D by E residues, and shortening of the
hydrophilic polyserine tract were tolerated, however. We
found that a short, thiol-functionalized peptide, CDDZ, was
∼25% more eﬀective than SSSSSSDDZ at stabilizing IONPs.
Dynamic light scattering (DLS) analysis of IONP cores
complexed with CDDZ (Figure 1c) indicated a hydrodynamic
radius of 5.8 ± 0.7 nm, and transmission electron microscopy
(TEM) of the material (inset) showed single, compact,
electron-dense cores of 6.1 ± 0.2 nm diameter separated by
gaps of 0.89 ± 0.03 nm; this result was also consistent with
TEM data obtained in negative stain (Supporting Information).
The zeta potential of CDDZ−IONP complexes was
determined to be −20.9 mV (Supporting Information).
These measurements are consistent with a nanoparticle
structure in which individual cores from the oleate-stabilized
starting material are coated and stabilized by a thin layer of
anionic peptides. The results also suggested that the DDZ motif
might be a generalizable anchor from which further libraries of
polypeptide−IONP conjugates could be formed and screened
for functional characteristics.
We used these ﬁndings as a basis for synthesis of a further
collection of 39 peptide sequences, leading to a library of 55
peptides in total, and assessed these peptides for their ability
yield eﬀective contrast agents for MRI. This approach enabled
us to examine the dependence of MRI contrast induction in
parallel on a variety of parameters, such as hydrophilicity,
charge, peptide length, and the presence of speciﬁc functional
groups or sequence motifs. Twenty-eight out of the 55
peptide−IONP complexes formed showed OD450 values within
30% of the maximum value, indicating relative stability in PBS.
These conjugates were examined by MRI and by DLS (Figure
2a and Supporting Information). MRI data obtained consisted
of measurements of the apparent longitudinal and transverse
relaxivity, r1 and r2, which reﬂect the ability of each IONP
Figure 1. Identiﬁcation of stable peptide−IONP complexes. (a)
Schematic of peptide−IONP library production. Oleate-stabilized iron
oxide cores are exchanged into TMA/water mixtures, library peptides
(50 μM) are added to IONP aliquots (4.2 mM Fe), and suspensions
are neutralized with PBS. Samples are arrayed into microtiter plates for
imaging-based assays. (b) A small library of candidate IONP ligands
was screened for ability to stabilize cores in PBS. Greater relative
absorbance values indicate more eﬀective stabilization. Design
rationales for each peptide are noted on the left, and sequences
reported to their right, with color coding to denote positively charged
residues (cyan), negatively charged residues (red), iron oxide binding
groups (green), and hydrophilic residues (gray). Error bars denote
s.e.m. of three independent measurements. On the far right-hand side,
images are given illustrating formation of pellets (dark spots) or lack
thereof, following centrifugation of representative samples. (c)
Dynamic light scattering and transmission electron micrographic
data (inset) illustrating size parameters of the CDDZ−IONP complex.
Scale bar = 20 nm.
Figure 2. Analysis of peptide−IONP libraries. (a) Characterization of
28 peptide−IONP complexes that passed initial screening for stability
from a library of 55 candidates. Each peptide−IONP complex is
represented by an open circle centered on coordinates corresponding
to its measured relaxivity values (r1 and r2) at 7 T. DLS radius
measurements from each species are indicated by symbol sizes (key on
right), and fractional contents of DOPA residues (Z/N) are indicated
by the color scale. Individual measurements are reported by peptide
sequence in Supporting Information. (b) Properties of optimized
contrast agents selected for consistent high r2 values [dashed box in
(a)]. Relaxivity values, estimated pI, and fractional DOPA content all
diﬀered signiﬁcantly from the rest of the library. T1- and T2-weighted
MRI scans illustrating contrast produced by these peptide−IONP
complexes (500 μM Fe) are inset at left (TE/TR = 10/477) and right
(TE/TR = 40/3125), respectively. Error margins reﬂect s.e.m. (n = 3).
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reagent to produce contrast in T1- and T2-weighted imaging,
respectively. Mean values of r1, r2, and DLS radius across the
library were 1.8 ± 0.2 (mM Fe)−1 s−1, 37 ± 6 (mM Fe)−1 s−1,
and 25 ± 5 nm, respectively.
The data of Figure 2a yield a number of notable results. First,
dramatic variation of both r1 and r2, from a maximum r2/r1 ratio
of 380 ± 150 to a minimum of 4.4 ± 1.4, is apparent among
peptide−IONP complexes. This suggests that determinants of
r1 and r2 are separable, perhaps due to diﬀerential eﬀects of the
peptide ligands on the inner vs outer sphere interactions of
water molecules with IONP cores, which underlie the MRI
contrast mechanism. Second, some variations in r2 are not
explained by diﬀerences in DLS radius, despite experimental
and theoretical accounts of nanoparticle relaxivity that depend
heavily on particle size.11 In particular, the highest r2 value of
123 ± 11 (mM Fe)−1 s−1 is displayed by an IONP complex
with sequence SSSCEEZ, which exhibits one of the smallest
hydrodynamic radii. Third, the highest r1 values are displayed
by IONP complexes with a set of peptides with 20% or higher
DOPA content, well above the average of 0.11 ± 0.01%. These
complexes also show uniformly compact size (DLS radii <23
nm), which could contribute mechanistically to their relatively
strong eﬀects on longitudinal relaxation.12 The most DOPA-
rich peptide in the library, SSSSDDZZZZ, displayed a relatively
low r1 [0.2 ± 0.1 (mM Fe)
−1 s−1] and large size (71 nm),
however.
The presence of a number of very large IONP complexes
with r2 < 30 (mM Fe)
−1 s−1 suggested that some of the
peptides promote agglomeration to sizes above the so-called
“static dephasing limit”, at which r2 decreases with apparent
size.13 Agglomeration is a dynamic process and can lead to
undesirable changes in MRI contrast over time. To screen
against such eﬀects, we compared r2 values obtained before and
after an incubation period and discovered that many conjugates
displayed instability (Supporting Information). Four peptide−
IONP complexes showed optimal properties, however, with
substantial r2 values with variation of less than 25%. The
corresponding ligand sequences were all DOPA-rich peptides
that also produced high r1 values in Figure 2a (dashed box).
The properties of these sequences were examined in greater
detail (Figure 2b). With respect to the rest of the library, the
four peptides showed signiﬁcantly lower pI (p < 10−6), in
addition to higher DOPA content (p = 0.025) and r1 (p <
10−6). Within the set, some variation of r1 and r2 was also
observed; the r1 diﬀerence between CDDZ and SSSSDDZZ
was signiﬁcant (p = 0.05), suggesting the possibility that
microstructural diﬀerences even among this narrow set of
sequences can inﬂuence relaxivity.
To test the ability of optimized peptide−IONP complexes to
function as MRI contrast agents in vivo, we examined the
behavior of CDDZ−IONP in biological buﬀer and in mice.
Incubation of the particles (4.2 mM Fe, 50 μM peptide) in 10%
fetal bovine serum (FBS) resulted in ∼10% change in optical
absorbance over a 5 h period, and stability could be further
prolonged by adding excess CDDZ (Figure 3a). Intravenous
injection of 150 μL of CDDZ−IONP aliquots containing 4 mM
Fe and 500 μM peptide into mice (Figure 3b,c) resulted in T2-
weighted MRI changes that persisted for up to 12 h and
corresponded to T2 decreases of close to 20% in muscle tissue
(signiﬁcant at 1 and 12 h with t-test p = 0.016 and 0.013,
respectively).
Both the screening approach and speciﬁc results we report
on here could have general applicability to the design of
molecular imaging reagents. Discovery of optimized peptide−
IONP MRI T2 contrast agents was enabled by our ability to
screen a large collection of sequences for MRI and colloidal
properties; this was in turn enabled by identiﬁcation of the
DDZ motif as a basic building block for forming IONP
complexes, and rejection of alternative motifs. Results of the
study show that the combination of catechol and carboxylate
groups in peptide ligands promotes, but is not suﬃcient for
stabilizing colloidal iron oxide cores. By screening peptide
complexes for MRI properties, we found considerable diversity
of r1 and r2 values, which is likely to reﬂect fundamental
mechanisms of contrast generation by IONP agents. In the
future, these ﬁndings might become bases for synthesis of
isomorphous peptide−IONP complexes with diﬀerent r2/r1
ratios for dual-probe molecular imaging applications, or for
design of responsive MRI contrast agents in which peptide−
IONP interactions are explicitly modulated. The peptide ligand
family we demonstrate here incorporates a non-genetically
encodable amino acid, DOPA; this limits possible application of
genetic techniques for generating IONP ligand libraries, but
fusion of DOPA moieties into genetically encoded libraries
might still be possible using various chemical approaches.14,15
Screening of new reagents for MRI and other applications will
be most straightforward if based on synthetic peptides, where
analysis of libraries of over 103 molecules is feasible.16
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Figure 3. Biostability and in vivo MRI contrast induced by a peptide−
IONP complex. (a) UV−visible spectra of CDDZ−IONP (3.6 mM Fe,
450 μM peptide) incubated for varying lengths of time in a 10% FBS
biomimetic solution. Near invariance of the spectrum indicates relative
stability of the particles in a biomimetic milieu. (b) T2 maps obtained
from a representative mouse injected with 150 μL of CDDZ−IONP
suspension (4 mM Fe, 500 μM peptide) and imaged by MRI at 7 T
both before (left) and 1 h after (right) tail vein infusion. T2 shortening
is visible in the musculature surrounding the spinal column
(arrowheads), and the dorsoventral (D-V) axis and liver (L) are
identiﬁed to facilitate orientation. (c) Group T2 measurements from
the perispinal musculature of animals injected with contrast agent and
imaged pre-injection and 1 and 12 h following injection. Error bars
denote s.e.m. over multiple animals (n = 3).
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